PDF herunterladen
Hamostaseologie 2023; 43(01): 067-074
DOI: 10.1055/a-1987-3682
Review Article

Immune Plasma for the Treatment of COVID-19: Lessons Learned so far

Hubert Schrezenmeier
1   Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and, University Hospital Ulm, Ulm, Germany
2   Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
,
Simone Hoffmann
1   Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and, University Hospital Ulm, Ulm, Germany
2   Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
,
Henrike Hofmann
1   Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and, University Hospital Ulm, Ulm, Germany
2   Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
,
Thomas Appl
1   Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and, University Hospital Ulm, Ulm, Germany
2   Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
,
Bernd Jahrsdörfer
1   Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and, University Hospital Ulm, Ulm, Germany
2   Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
,
Erhard Seifried
3   Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-Württemberg – Hessen, Frankfurt, Germany
,
Sixten Körper
1   Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and, University Hospital Ulm, Ulm, Germany
2   Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

COVID-19 convalescent plasma (CCP) has been explored as one of the treatment options for COVID-19. Results of many cohort studies and clinical trials have been recently published. At first glance, the results of the CCP studies appear to be inconsistent. However, it became clear that CCP is not beneficial if CCP with low anti-SARS-CoV-2 antibody concentrations is used, if it is administered late in advanced disease stages, and to patients who already mounted an antibody response against SARS-CoV-2 at the time of CCP transfusion. On the other hand, CCP may prevent progression to severe COVID-19 when very high-titer CCP is given early in vulnerable patients. Immune escape of new variants is a challenge for passive immunotherapy. While new variants of concern developed resistance to most clinically used monoclonal antibodies very rapidly, immune plasma from individuals immunized by both a natural SARS-CoV-2 infection and SARS-CoV-2 vaccination retained neutralizing activity against variants. This review briefly summarizes the evidence on CCP treatment to date and identifies further research needs. Ongoing research on passive immunotherapy is not only relevant for improving care for vulnerable patients in the ongoing SARS-CoV-2 pandemic, but even more as a model for passive immunotherapy in case of future pandemics with a newly evolving pathogen. Compared to other drugs, which must be newly developed in a pandemic (e.g., monoclonal antibodies, antiviral drugs), convalescent plasma is rapidly available, inexpensive to produce, and can be adaptive to viral evolution by selection of contemporary convalescent donors.

Keywords

immune plasma - convalescent plasma - COVID-19 - vaccination


Publikationsverlauf

Eingereicht: 28. Oktober 2022

Angenommen: 24. November 2022

Artikel online veröffentlicht:
20. Februar 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Shah V, Ko Ko T, Zuckerman M. et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol 2020; 190 (05) e279-e282
    PubMedGoogle Scholar
  • 2 Sahu T, Verma HK, Lvks B. Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: warrants a clear therapeutic strategy. World J Virol 2022; 11 (04) 204-207
    CrossrefPubMedGoogle Scholar
  • 3 Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, Palmieri C. Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis. JAMA Netw Open 2022; 5 (05) e2210880
    CrossrefPubMedGoogle Scholar
  • 4 Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood 2022; 140 (03) 236-252
    CrossrefPubMedGoogle Scholar
  • 5 Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130 (04) 1545-1548
    CrossrefPubMedGoogle Scholar
  • 6 Bloch EM, Shoham S, Casadevall A. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 130 (06) 2757-2765
    CrossrefPubMedGoogle Scholar
  • 7 Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?. Vox Sang 2020; 115 (06) 488-494
    CrossrefPubMedGoogle Scholar
  • 8 Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211 (01) 80-90
    CrossrefPubMedGoogle Scholar
  • 9 Joyner MJ, Carter RE, Senefeld JW. et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med 2021; 384 (11) 1015-1027
    CrossrefPubMedGoogle Scholar
  • 10 US Food and Drug Administration (FDA). FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administration's fight against pandemic. Accessed December 10, 2022 at: https://www.Fda.gov/news-events/press-announcements/fda-issuesemergency-use-authorization-convalescentplasma-potential-promising-covid-19-treatment
    PubMedGoogle Scholar
  • 11 Estcourt LJ, Roberts DJ. Convalescent plasma for COVID-19. BMJ 2020; 370: m3516
    CrossrefPubMedGoogle Scholar
  • 12 Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW. Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr 2022; 10 (04) e0092622
    CrossrefPubMedGoogle Scholar
  • 13 McConnell D, Harte M, Walsh C. et al. Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis. Sci Rep 2022; 12 (01) 17561
    CrossrefPubMedGoogle Scholar
  • 14 Jayk Bernal A, Gomes da Silva MM, Musungaie DB. et al; MOVe-OUT Study Group. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med 2022; 386 (06) 509-520
    CrossrefPubMedGoogle Scholar
  • 15 Hammond J, Leister-Tebbe H, Gardner A. et al; EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 2022; 386 (15) 1397-1408
    CrossrefPubMedGoogle Scholar
  • 16 Gottlieb RL, Vaca CE, Paredes R. et al; GS-US-540-9012 (PINETREE) Investigators. Early remdesivir to prevent progression to severe COVID-19 in Outpatients. N Engl J Med 2022; 386 (04) 305-315
    CrossrefPubMedGoogle Scholar
  • 17 Focosi D, Franchini M. Passive immunotherapies for COVID-19: The subtle line between standard and hyperimmune immunoglobulins is getting invisible. Rev Med Virol 2022; 32 (04) e2341
    CrossrefPubMedGoogle Scholar
  • 18 ITAC (INSIGHT 013) Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet 2022; 399 (10324): 530-540
    CrossrefPubMedGoogle Scholar
  • 19 Li L, Zhang W, Hu Y. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324 (05) 460-470
    CrossrefPubMedGoogle Scholar
  • 20 Estcourt LJ, Turgeon AF, McQuilten ZK. et al; Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 2021; 326 (17) 1690-1702
    CrossrefPubMedGoogle Scholar
  • 21 Bar KJ, Shaw PA, Choi GH. et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest 2021; 131 (24) 131
    CrossrefPubMedGoogle Scholar
  • 22 De Santis GC, Oliveira LC, Garibaldi PMM. et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerg Infect Dis 2022; 28 (03) 548-555
    CrossrefPubMedGoogle Scholar
  • 23 Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. PLACID Trial Collaborators. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020; 371: m3939
    CrossrefPubMedGoogle Scholar
  • 24 Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E. et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv 2020:2020.08.26.20182444
    PubMedGoogle Scholar
  • 25 AlQahtani M, Abdulrahman A, Almadani A. et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci Rep 2021; 11 (01) 9927
    CrossrefPubMedGoogle Scholar
  • 26 Simonovich VA, Burgos Pratx LD, Scibona P. et al; PlasmAr Study Group. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med 2021; 384 (07) 619-629
    CrossrefPubMedGoogle Scholar
  • 27 Holm K, Lundgren MN, Kjeldsen-Kragh J. et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Res Notes 2021; 14 (01) 440
    CrossrefPubMedGoogle Scholar
  • 28 Menichetti F, Popoli P, Puopolo M. et al; TSUNAMI Study Group. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Netw Open 2021; 4 (11) e2136246
    CrossrefPubMedGoogle Scholar
  • 29 Kirenga B, Byakika-Kibwika P, Muttamba W. et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Respir Res 2021; 8 (01) 8
    CrossrefPubMedGoogle Scholar
  • 30 Korley FK, Durkalski-Mauldin V, Yeatts SD. et al; SIREN-C3PO Investigators. Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med 2021; 385 (21) 1951-1960
    CrossrefPubMedGoogle Scholar
  • 31 Gharbharan A, Jordans CCE, Geurtsvankessel C. et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv 2020:2020.10.25.20219337
    PubMedGoogle Scholar
  • 32 Ray Y, Paul SR, Bandopadhyay P. et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv 2020; 16957608
    PubMedGoogle Scholar
  • 33 Devos T, Van Thillo Q, Compernolle V. et al; DAWn-Plasma Investigators. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J 2022; 59 (02) 2101724
    CrossrefPubMedGoogle Scholar
  • 34 Ortigoza MB, Yoon H, Goldfeld KS. et al; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Intern Med 2022; 182 (02) 115-126
    CrossrefPubMedGoogle Scholar
  • 35 Körper S, Weiss M, Zickler D. et al; CAPSID Clinical Trial Group. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest 2021; 131 (20) e152264
    CrossrefPubMedGoogle Scholar
  • 36 Sekine L, Arns B, Fabro BR. et al; PLACOVID Study Group. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J 2022; 59 (02) 2101471
    CrossrefPubMedGoogle Scholar
  • 37 Bégin P, Callum J, Jamula E. et al; CONCOR-1 Study Group. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med 2021; 27 (11) 2012-2024
    CrossrefPubMedGoogle Scholar
  • 38 RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; 397 (10289): 2049-2059
    CrossrefPubMedGoogle Scholar
  • 39 Balcells ME, Rojas L, Le Corre N. et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial. PLoS Med 2021; 18 (03) e1003415
    CrossrefPubMedGoogle Scholar
  • 40 O'Donnell MR, Grinsztejn B, Cummings MJ. et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest 2021; 131 (13) e150646
    CrossrefPubMedGoogle Scholar
  • 41 Bajpai M, Maheshwari A, Dogra V. et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). BMJ Open 2022; 12 (04) e055189
    CrossrefPubMedGoogle Scholar
  • 42 Thorlacius-Ussing L, Brooks PT, Nielsen H. et al. A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. Sci Rep 2022; 12 (01) 16385
    CrossrefPubMedGoogle Scholar
  • 43 van den Berg K, Glatt TN, Vermeulen M. et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Sci Rep 2022; 12 (01) 2552
    CrossrefPubMedGoogle Scholar
  • 44 Libster R, Marc GPR, Wappner D. et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv 2020; DOI: 10.1101/2020.11.20.20234.
    CrossrefPubMedGoogle Scholar
  • 45 Sullivan DJ, Gebo KA, Shoham S. et al. Early outpatient treatment for COVID-19 with convalescent plasma. N Engl J Med 2022; 386 (18) 1700-1711
    CrossrefPubMedGoogle Scholar
  • 46 Millat-Martinez P, Gharbharan A, Alemany A. et al; CoV-Early Study Group, COnV-ert Study Group. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat Commun 2022; 13 (01) 2583
    CrossrefPubMedGoogle Scholar
  • 47 Alemany A, Millat-Martinez P, Corbacho-Monné M. et al; CONV-ERT Group. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med 2022; 10 (03) 278-288
    CrossrefPubMedGoogle Scholar
  • 48 Gharbharan A, Jordans C, Zwaginga L. et al; CoV-Early Study Group. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial. Clin Microbiol Infect 2022:S1198-743X(22)00421-9
    PubMedGoogle Scholar
  • 49 Estcourt LJ, Cohn CS, Pagano MB. et al. Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma. Ann Intern Med 2022; 175 (09) 1310-1321
    CrossrefPubMedGoogle Scholar
  • 50 Klassen SA, Senefeld JW, Johnson PW. et al. Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv 2020; DOI: 10.1101/2020.07.29.20162917.
    CrossrefPubMedGoogle Scholar
  • 51 de Candia P, Prattichizzo F, Garavelli S. et al. Effect of time and titer in convalescent plasma therapy for COVID-19. iScience 2021; 24 (08) 102898
    CrossrefPubMedGoogle Scholar
  • 52 Libster R, Pérez Marc G, Wappner D. et al; Fundación INFANT–COVID-19 Group. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med 2021; 384 (07) 610-618
    CrossrefPubMedGoogle Scholar
  • 53 Gharbharan A, Jordans CCE, GeurtsvanKessel C. et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun 2021; 12 (01) 3189
    CrossrefPubMedGoogle Scholar
  • 54 Nguyen D, Simmonds P, Steenhuis M. et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill 2021; 26 (27) 26
    CrossrefPubMedGoogle Scholar
  • 55 Wouters E, Steenhuis M, Schrezenmeier H. et al. Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. Vox Sang 2021; 116 (05) 493-496
    CrossrefPubMedGoogle Scholar
  • 56 Weinreich DM, Sivapalasingam S, Norton T. et al; Trial Investigators. REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med 2021; 385 (23) e81
    CrossrefPubMedGoogle Scholar
  • 57 Rijnders BJA, Huygens S, Mitjà O. Evidence-based dosing of convalescent plasma for COVID-19 in future trials. Clin Microbiol Infect 2022; 28 (05) 667-671
    CrossrefPubMedGoogle Scholar
  • 58 Körper S, Grüner B, Zickler D. et al. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. J Clin Invest 2022; e163657
    CrossrefPubMedGoogle Scholar
  • 59 Salazar E, Perez KK, Ashraf M. et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol 2020; 190 (08) 1680-1690
    CrossrefPubMedGoogle Scholar
  • 60 Marconato M, Abela IA, Hauser A. et al. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. J Clin Invest 2022; 132 (12) e158190
    CrossrefPubMedGoogle Scholar
  • 61 Horby PW, Estcourt L, Eto L. et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv 2021:2020.06.22.20137273
    PubMedGoogle Scholar
  • 62 Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E. et al; ConPlas-19 Study Group. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest 2021; 131 (20) e152740
    CrossrefPubMedGoogle Scholar
  • 63 Aydillo T, Gonzalez-Reiche AS, Aslam S. et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 2020; 383 (26) 2586-2588
    CrossrefPubMedGoogle Scholar
  • 64 DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity 2022; 55 (10) 1779-1798
    CrossrefPubMedGoogle Scholar
  • 65 Shah V, Ko Ko T, Zuckerman M. et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol 2020; 190 (05) e279-e282
    CrossrefPubMedGoogle Scholar
  • 66 Thompson MA, Henderson JP, Shah PK. et al; COVID-19 and Cancer Consortium. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol 2021; 7 (08) 1167-1175
    CrossrefPubMedGoogle Scholar
  • 67 Hueso T, Godron AS, Lanoy E. et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia 2022; 36 (04) 1025-1034
    CrossrefPubMedGoogle Scholar
  • 68 Biernat MM, Kolasińska A, Kwiatkowski J. et al. Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19. Viruses 2021; 13 (03) 13
    CrossrefPubMedGoogle Scholar
  • 69 Lanza F, Monaco F, Ciceri F. et al. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: an Italian retrospective study. Hematol Oncol 2022
    PubMedGoogle Scholar
  • 70 Cristelli MP, Langhi Junior DM, Viana LA. et al. Efficacy of convalescent plasma to treat mild to moderate COVID-19 in kidney transplant patients: a propensity score matching analysis. Transplantation 2022; 106 (01) e92-e94
    CrossrefPubMedGoogle Scholar
  • 71 Müller-Tidow C, Janssen M, Schäkel U. et al. A randomized controlled clinical trial demonstrates that plasma from convalescent and vaccinated donors improves outcome of COVID-19 in patients with hematological disease, cancer or immunosuppression. [abstract]. EHA Library 2022; 357146
    PubMedGoogle Scholar
  • 72 Lacombe K, Hueso T, Porcher R. et al. Efficacy and safety of convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized clinical trial. medRxiv 2022; http://medrxiv.org/content/early/2022/08/10/2022.08.09.22278329.abstract:2022
    PubMedGoogle Scholar
  • 73 Senefeld JW, Franchini M, Mengoli C. et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review. medRxiv 2022;2022
    PubMedGoogle Scholar
  • 74 Wang Z, Muecksch F, Schaefer-Babajew D. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021; 595 (7867): 426-431
    CrossrefPubMedGoogle Scholar
  • 75 Lustig Y, Nemet I, Kliker L. et al. Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2. N Engl J Med 2021; 384 (25) 2453-2454
    CrossrefPubMedGoogle Scholar
  • 76 Stamatatos L, Czartoski J, Wan YH. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 2021; 372 (6549): 1413-1418
    CrossrefPubMedGoogle Scholar
  • 77 Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med 2022; 386 (07) 698-700
    CrossrefPubMedGoogle Scholar
  • 78 Wilhelm A, Widera M, Grikscheit K. et al. Limited neutralisation of the SARS-CoV-2 omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine 2022; 82: 104158
    CrossrefPubMedGoogle Scholar
  • 79 Liu L, Iketani S, Guo Y. et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature 2022; 602 (7898): 676-681
    CrossrefPubMedGoogle Scholar
  • 80 Planas D, Saunders N, Maes P. et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature 2022; 602 (7898): 671-675
    CrossrefPubMedGoogle Scholar
  • 81 Cameroni E, Bowen JE, Rosen LE. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature 2022; 602 (7898): 664-670
    CrossrefPubMedGoogle Scholar
  • 82 Seidel A, Jahrsdörfer B, Körper S. et al. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 delta and omicron that can be predicted by anti-S antibody concentrations in serological assays. medRxiv 2022; http://medrxiv.org/content/early/2022/01/17/2022.01.17.22269201
    PubMedGoogle Scholar
  • 83 Nguyen D, Simmonds P, Steenhuis M. et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill 2021; 26 (27) 26
    CrossrefPubMedGoogle Scholar